HTTIF (HighTide Therapeutics) Book Value per Share: $0.09 (As of Dec. 2025)


HTTIF HighTide Therapeutics Inc HTTIF
14 GF Score
Price $0.39
! 3 Warning Signs
View Full Analysis

What is HighTide Therapeutics Book Value per Share?

HighTide Therapeutics HTTIF 14 Book Value per Share is $0.09 as of Dec. 2025. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

HighTide Therapeutics's book value per share for the quarter that ended in Dec. 2025 was $0.09.

During the past 12 months, HighTide Therapeutics's average Book Value Per Share Growth Rate was -24.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

HighTide Therapeutics's current price is $0.3893. Its book value per share for the quarter that ended in Dec. 2025 was $0.09. Hence, today's PB Ratio of HighTide Therapeutics is 4.53.

During the past 5 years, the highest P/B Ratio of HighTide Therapeutics was 4.02. The lowest was 0.00. And the median was 0.00.


HighTide Therapeutics  (OTCPK:HTTIF) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


HighTide Therapeutics Book Value per Share Related Terms


HighTide Therapeutics Book Value per Share Historical Data

* Premium members only.

The historical data trend for HighTide Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HighTide Therapeutics Book Value per Share Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Book Value per Share
-0.08 -0.27 0.19 0.11 0.09

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Book Value per Share Get a 7-Day Free Trial Premium Member Only 0.19 0.15 0.11 0.09 0.09

HTTIF vs VRTX, REGN, ALNY: Book Value per Share Comparison

For the Biotechnology subindustry, HighTide Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HighTide Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's PB Ratio falls into.


HTTIF
14GF Score
HighTide Therapeutics Inc HTTIF
Book Value per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HighTide Therapeutics Book Value per Share Calculation

HighTide Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(43.59-0.00)/508.72
=0.09

HighTide Therapeutics's Book Value Per Share for the quarter that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(43.59-0.00)/508.72
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of $0.09 mean?
HighTide Therapeutics (HTTIF) has a Book Value per Share of $0.09 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on HighTide Therapeutics and its competitors.
Is HighTide Therapeutics' Book Value per Share too high?
HighTide Therapeutics' current Book Value per Share is $0.09. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' Book Value per Share compare to VRTX and REGN?
HighTide Therapeutics' Book Value per Share of $0.09 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on HighTide Therapeutics and its competitors. HighTide Therapeutics's current Book Value per Share is $0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current Book Value per Share of $0.09. The current Book Value per Share is $0.09. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current Book Value per Share is $0.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HighTide Therapeutics Business Description

Other Exchanges 02511:Hong Kong
Address Fubao Street, 9th to 10th Floor, Building D, Shenfang Park, Futian District, Shenzhen-Hong Kong Science and, Technology Innovation Cooperation Zone, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score

Get the complete analysis for HTTIF

Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price